Qumis | $2,200,000 | (Jan 22, 2025)
Zynap | $5,937,902 | (Jan 22, 2025)
Belfry | $12,000,000 | (Jan 22, 2025)
Certified by Founder
Lodge
Tome Biosciences
start up
United States
- Watertown, Massachusetts
- 14/12/2023
- Series B
- $213,000,000
Tome Biosciences is the programmable genomic integration (PGI) company. Our technologies allow us to insert any genetic sequence of any size at any location in the genome with site-specific precision. We are writing the final chapter in genomic medicines, delivering cures to patients through cell and integrative gene therapies.
- Industry Biotechnology Research
- Website https://tome.bio/
- LinkedIn https://www.linkedin.com/company/tome-biosciences/about/
Gravity | $13,000,000 | (Jan 22, 2025)
LeapXpert | $20,000,000 | (Jan 22, 2025)
BPR Hub | $2,600,000 | (Jan 22, 2025)
NovoLINC | Undisclosed Amount | (Jan 22, 2025)
IntusCare | $11,500,000 | (Jan 21, 2025)
ecoplanet | $16,571,680 | (Jan 21, 2025)
Sereact | $25,894,660 | (Jan 21, 2025)
Fundment | $55,157,175 | (Jan 21, 2025)
Men In Blazers Media Network | $150,000,000 | (Jan 21, 2025)